Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TOP1 | P11387 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243024 | 1.00 | KCNH2 (0.53) | KCNH2CYP3A4KDM4EHPGDALDH1A1 | |
| SCHEMBL739709 | 1.00 | KCNH2 (0.53) | KCNH2CYP3A4KDM4EHPGDALDH1A1 | |
| SCHEMBL31256774 | 1.00 | KCNH2 (0.53) | KCNH2CYP3A4KDM4EHPGDALDH1A1 | |
| SCHEMBL4083952 | 1.00 | KCNH2 (0.53) | KCNH2CYP3A4KDM4EHPGDALDH1A1 | |
| SCHEMBL15090911 | 1.00 | KCNH2 (0.53) | KCNH2CYP3A4KDM4EHPGDALDH1A1 | |
| SCHEMBL15090909 | 1.00 | KCNH2 (0.53) | KCNH2CYP3A4KDM4EHPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL4088987 | 0.99 | KCNH2 (0.52) | KCNH2CYP3A4KDM4EHPGDALDH1A1 | |
| Water SCHEMBL2244068 | 0.99 | KCNH2 (0.52) | KCNH2CYP3A4KDM4EHPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL4088995 | 0.99 | KCNH2 (0.52) | KCNH2CYP3A4KDM4EHPGDALDH1A1 | |
| Water SCHEMBL2244073 | 0.99 | KCNH2 (0.52) | KCNH2CYP3A4KDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882689-B1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-07-10 | — | — | EP | claimed |
| US-8211910-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | claimed |
| US-9937192-B2 | Combination therapy to treat mycobacterium diseases | SPERO TRINEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937192-B2 | Combination therapy to treat mycobacterium diseases | SPERO TRINEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9572809-B2 | Combination therapy to treat Mycobacterium diseases | SPERO TRINEM, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9572809-B2 | Combination therapy to treat Mycobacterium diseases | SPERO TRINEM, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2000467-B1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| EP-2000467-B1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| US-20140045791-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | SPERO THERAPEUTICS, INC. | 2014-02-13 | — | — | US | disclosed |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2000467-A2 | HYDRATE FOR MEDICAL PURPOSES | Daiichi Sankyo Company, Limited (JP) | 2008-12-10 | — | — | EP | disclosed |
| EP-2000467-A2 | HYDRATE FOR MEDICAL PURPOSES | Daiichi Sankyo Company, Limited (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1930321-A1 | PROCESS FOR PREPARATION OF TETRASUBSTITUTED 5-AZASPIRO[2.4]- HEPTANE DERIVATIVES AND OPTICALLY ACTIVE INTERMEDIATES THEREOF | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1882685-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-1882689-A1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| WO-2007111023-A1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-10-04 | — | — | WO | disclosed |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | NQO2, TREH, CYP51A1 | KCNH2 2623/4885CYP3A4 314/4885KDM4E 2681/4885 |
| US-20170128471-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | TOP1, TOP2A, TOP2B | KCNH2 4056/4885CYP3A4 239/4885KDM4E 2466/4885 |
| US-20140045791-A1 | COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES | TOP1, TOP2A, TOP2B | KCNH2 4056/4885CYP3A4 239/4885KDM4E 2466/4885 |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | QTRT1, RRS1, LAS1L | KCNH2 1399/4885CYP3A4 871/4885KDM4E 2926/4885 |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | ACSL3, ARL1, NQO2 | KCNH2 670/4885CYP3A4 133/4885KDM4E 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.